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The members of the TLR family share a cytoplasmic domain similar to a portion of the interleukin-1 receptor (IL-1R), known as the Toll/IL-1R homologous region or TIR domain. As a result, TLRs activate signaling pathways that are similar to those engaged by IL-1. The TIR domain recruits the adaptor protein myeloid differentiation primary response gene 88 (MyD88), which activates IL-1R-associated kinases. IL-1R-associated kinases in turn activate the tumor necrosis factor (TNF) receptor-associated factor 6, eliciting downstream signaling via nuclear factor-B (NF-B) and mitogenactivated protein kinase pathways. The MyD88-dependent pathway is shared by all TLRs, with the exception of TLR-3. TLR-4 signaling is the most complex and encompasses both the MyD88-dependent and the MyD88-independent pathways. 1, 3 The MyD88-independent pathway, engaged by TLR-3 and -4, relies on TIR-domain-containing adaptor protein inducing interferon-␤ (TRIF) to mediate interferon regulatory factor-3 and NF-B activation. 3 TLR-4 utilizes TRIF-related adaptor molecule (TRAM) to interact with TRIF and engage the MyD88-independent pathway. [3] [4] [5] Toll/IL-1R signaling is involved in the development of aortic lesions in murine atherosclerosis. Crossing of MyD88 Ϫ/Ϫ with apolipoprotein E Ϫ/Ϫ mice has been shown to reduce the development of atherosclerotic lesions by Ϸ60%. 6 Interruption of IL-1 signaling reduces atherosclerotic lesion formation from 40% to 67%. 7, 8 Similarly, targeted deletion of TLR-4 or TLR-2 in apolipoprotein E Ϫ/Ϫ mice resulted in a 55% reduction of atherosclerotic lesion development. 9 -12 Local delivery of lipopolysaccharide affects arterial remodeling after arterial injury. 13 Exposure to synthetic TLR-2 ligands or live bacteria induces a significant increase in atherosclerosis 10, 12 and neointima formation. 14 TLR-2 expression is increased in endothelial cells at regions of susceptibility of atherosclerosis, and it is associated with monocyte recruitment. 15 Notwithstanding the evidence of the role of TLR signaling in experimental models of atherosclerosis, the functional role of TLRs in human atherosclerosis is yet to be proved. Increased expression of TLR-1, -2, and -4 is found in macrophages and resident vascular cells in human atherosclerosis. 16 Two cosegregating TLR-4 gene point mutations (Asp299Gly and Thr399Ile) related to a blunted response to inhaled lipopolysaccharide have been investigated with contradictory results. For instance, the TLR-4/Asp399Gly polymorphism has been associated with a reduced intima-media carotid thickness. 17 However, in the Carotid Artery Progression Study, this polymorphism was not linked to intimamedia thickness or plaque progression over a 3-year followup. 18 Both polymorphisms have been found at a higher frequency in a cohort of patients with myocardial infarction. 19 The TLR-2 polymorphism Arg753Gln, shown to confer susceptibility to mycobacteria infection, was associated with restenosis after coronary angioplasty. 20 Finally, most studies on TLR-2 and TLR-4 in human atherosclerotic diseases have been performed with the use of peripheral blood monocytes. Patients with acute coronary syndromes but not stable angina have an increased expression of TLR-2 and -4 on circulating monocytes. 21, 22 Such increase in expression does not always result in enhanced TLR signaling. 21, 23, 24 Therefore, there is currently little information on whether TLR signaling is protective or detrimental at lesion sites in human atherosclerosis.
We have previously shown the feasibility of isolating viable cells from human carotid atherosclerotic lesions from patients undergoing surgical endarterectomy. This system models the cellular interactions taking place in vivo and permits the direct investigation of signaling pathways. This complex mixture contains macrophages, lymphocytes, and smooth muscle cells and displays in culture a spontaneous production of proinflammatory cytokines, chemokines, and matrix metalloproteinases (MMPs). 25 Such dysregulated production depends on the NF-B pathway and could be significantly prevented by blocking IB kinase-␤ activity. 25 Given the variety of receptors signaling through NF-B, the upstream determinants of NF-B activation in human atherosclerosis are still unknown.
Genetic deletions of TLR-2, TLR-4, IL-1, and MyD88 signaling, all leading to NF-B activation, have an equivalent effect on murine atherosclerosis. 6, 9, 10 Here we show that, in human atherosclerosis, TLR-2 and MyD88 play a predominant role in NF-B activation and in the production of inflammatory mediators and even matrix-degrading enzymes.
Methods

Patient Population and Sample Collection
Carotid endarterectomies from 58 patients undergoing revascularization procedures for symptomatic carotid disease were obtained at Charing Cross Hospital, London. The protocol was approved by the Research Ethics Committee. All patients gave written informed consent, according to the Human Tissue Act 2004 (UK).
Ex Vivo Culture of Cells Isolated From Human Atherosclerotic Plaques
Diseased intimal arterial segments were dissected from carotid endarterectomy specimens and single cell suspensions obtained by enzymatic digestion, as published previously. 25 The viable cell number obtained was 3Ϯ1.9ϫ10 6 (meanϮSEM). Phenotyping by flow cytometry (Methods in the online-only Data Supplement) confirmed our previous observation 25 
Blockers
Freshly isolated atheroma cells were cultured at 10 6 cells per milliliter in RPMI containing 10% fetal bovine serum (Biosera, UK) either alone or in the presence of anti-human TLR-2 (clone TL2.1, eBioscience) and TLR-4 (clone HTA125, Abcam) antibodies or isotype-control antibody (eBioscience) at a concentration of 25 g · mL Ϫ1 (based on dose-ranging experiments; data not shown). The antibodies used were selected for their efficacy in inhibiting TLR-4 and TLR-2 signaling in human umbilical vein endothelial cells 26 and primary macrophages 27 (Methods in the online-only Data Supplement; Figures II and III in the online-only Data Supplement). IL-1R antagonist (IL-1Ra) (R&D Systems) was used at a concentration of 10 g · mL Ϫ1 . Supernatants were removed after 24, 48, 72, and 96 hours and stored at Ϫ80°C for single-batch analysis of cytokine and MMP production via Luminex and zymography (Methods in the online-only Data Supplement). Viability was monitored with the use of 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium (MTT) (Sigma, UK). 28 NF-B activation on blockers was assessed via NF-B luciferase reporter assay 29 (Methods in the online-only Data Supplement). Each condition was tested in triplicate culture, and each triplicate was analyzed separately.
Adenoviral Vectors
E1/E3-deleted recombinant replication-deficient adenoviral vectors (serotype Ad5) encoding green fluorescent protein (GFP), either alone (control Ad) or with a dominant-negative (DN) form of MyD88 (AdMyD88 DN ) or TRAM (AdTRAM DN ), were generated as described. 27, 29, 30 Cells were plated at 10 6 cells per milliliter in RPMI and either left uninfected or infected in serum-free conditions for 2 hours with indicated adenoviruses at multiplicity of infection 200:1, which results in Ͼ90% infection efficiency, as shown previously. 25 After 48 and 72 hours, supernatants were removed and stored at Ϫ80°C. Cellular viability and NF-B activity were assessed. Successful infection was monitored via the GFP tag and immunoblotting (Methods in the online-only Data Supplement).
Statistical Analysis
Data were analyzed with Stata (version 10, StataCorp LP, Tex). We used nonparametric methods to account for the nonnormality of distributions. Rank ANCOVA was used to assess the effect of treatment with the indicated blockers, adjusted for time (in culture) as a covariate. Alternatively, the Wilcoxon rank sum test was used to assess the effect of blockers versus control when a single time point was used in the experiment. An ␣ level of 0.05 was considered statistically significant. All tests used were 2-tailed.
The authors had full access to and take full responsibility for the data. All authors have read and agree to the manuscript as written.
Results
MyD88 Signaling Plays a Key Role in Driving NF-B Activation and the Production of Proinflammatory Mediators and MMPs in Human Atheroma Cell Cultures
To evaluate the overall effect of blocking the TLR/IL-1 pathway, we first overexpressed a dominant-negative form of MyD88 in atheroma cell cultures through adenoviral gene transfer (AdMyd88 DN ). Successful overexpression of the transgenes, compared with endogenous levels, was demonstrated by the expression of adenovirus-contained GFP (Figure 1A and 1B) and immunoblotting ( Figure 1C ). There was no significant difference in viability between uninfected and adenovirus-infected cells ( Figure 1D ). Similarly, there was no difference in PI/annexin V staining between infected and uninfected cells in the overall cell population (Ͻ15% annexin V-and 5% PI-positive cells in all conditions) or in different cell types (data not shown).
Using an NF-B reporter gene under a luciferase promoter, we found that NF-B activation was inhibited in AdMyd88 DNinfected cells versus control-Ad-infected cells (PϽ0.05; Figure  1E ). AdMyD88 DN caused statistically significant decreases in the production of monocyte chemotactic protein-1 (MCP-1/CCL2; Pϭ0.000), IL-8/CXCL8 (Pϭ0.006), and IL-6 (Pϭ0.002; Figure  2A to 2C) but not TNF-␣ ( Table I in Table I in the onlineonly Data Supplement). These results indicate that MyD88dependent signaling is involved in inflammation and matrix degradation in human atherosclerotic plaques.
IL-1 Blockade Has Only a Partial Effect on NF-B Activation and Cytokine Production
Because MyD88 is shared by TLR and IL-1 signaling, we explored the effect of IL-1 blockade with a natural inhibitor of IL-1 activity, IL-1Ra. Treatment with IL-1Ra achieved reduction of NF-B activation (22Ϯ5%; Pϭ0.05; nϭ3; data not shown) and IL-6 (Pϭ0.009; 45Ϯ9% inhibition at 72 hours; Figure 3A ). However, there was no effect on MMP-3 ( Figure 3B ), MCP-1/CCL2, or other MyD88-dependent mediators in atheroma cell cultures (data not shown).
TLR-2 and TLR-4 Drive NF-B Activation
Because MyD88 but not IL-1 blockade resulted in reduction of several proatherogenic mediators, we assessed the functional relevance of alternative MyD88 activators, such as TLR-2 and TLR-4, using anti-TLR-2 and -4 blocking antibodies. To assess whether NF-B activation in human atheroma cell culture is dependent on TLR-2 and TLR-4, we utilized a NF-B luciferase reporter assay. TLR-2 and TLR-4 blocking antibodies caused 60Ϯ6% and 38Ϯ5% reduction, respectively, in NF-B activation compared with the isotype control (PϽ0.05; Figure 4A ). Such reduction of NF-B activity was not associated with changes in cell viability, as assessed by MTT assay ( Figure 4B ) or PI/annexin V staining (Ͻ15% annexin V-and 5% PI-positive cells in the overall cell population in all conditions).
TLR-2 Blockade Significantly Reduces Cytokine and Chemokine Production
We sought to evaluate whether TLR-2 and TLR-4 blockade would directly modulate the production of cytokines and chemokines in advanced human carotid atherosclerotic lesions. Culture of atheroma cells in the presence of anti-TLR-2 antibodies caused significant reduction in MCP-1/CCL2 (Pϭ0.000), IL-8/CXCL8 (Pϭ0.009), and IL-6 production (Pϭ0.000; Figure  5A , 5B, and 5D) compared with the isotype control, whereas TNF-␣ production was not affected ( Figure 5C ). Percent inhibitions at each time point are shown in Table II in the online-only Data Supplement. In contrast, the anti-TLR-4 antibody did not significantly affect the production of cytokines and chemokines ( Figure 5A through 5D) . Data are shown as meanϮSEM (nϭ6). No significant difference was observed between untreated cells and isotype controltreated cells (PϾ0.05; data not shown). TLR-2 blocking antibodies significantly reduced MCP-1 (***Pϭ0.000; A), IL-8 (*Pϭ0.009; B), IL-6 (***Pϭ0.000; D), MMP-1 (***Pϭ0.000; E), MMP-2 (**Pϭ0.004; F), MMP-3 (***Pϭ0.000; G), MMP-9 (*Pϭ0.006; H) production vs isotype control-treated cells. The TLR-4 blocking antibody (Ab) reduced MMP-3 (***Pϭ0.000; rank ANCOVA).
TLR-2 Blockade Significantly Reduces MMP Production in Human Atheroma Cell Cultures
The effect of TLR-2 and TLR-4 inhibition on the production of MMPs, a key step toward plaque vulnerability to rupture in humans, is unknown. Hence, we evaluated the outcome of exposing atheroma cell cultures to TLR-2 and -4 neutralizing antibodies and quantified the production of MMP-1, -2, -3, and -9. We found that in the presence of anti-TLR-2 antibodies, production of MMP-1, -2, -3, and -9 was significantly reduced (Pϭ0.000, Pϭ0.004, Pϭ0.000, and Pϭ0.006, respectively; Figure 5E to 5H). Reduction of MMP levels was confirmed by zymography ( Figure IV in the online-only Data Supplement). The effect of TLR-2 blockade was consistent across a larger donor group (nϭ16; Figure 6 ). Tissue inhibitor of matrix metalloproteinases-1 and extracellular matrix metalloproteinase inducer production was unaffected ( Table II in the online-only Data Supplement). Anti-TLR-4 antibodies had no statistically significant effect on MMP-1, -2, and -9 ( Figure 5E through 5H) but reduced MMP-3 production (Pϭ0.000; Figure 5G ).
Effect of TRAM Blockade on MMP Production
The lack of effect with TLR-4 neutralizing antibodies in the atheroma cell culture prompted us to use an alternative method of TLR-4 blockade, a dominant-negative form of the adaptor TRAM (TRAM DN ), which is used by TLR-4. 3 Overexpression of TRAM DN (Figure Va Figure  7D and 7E) but did not achieve statistically significant inhibition of the production of the other mediators ( Figure 7A through 7C and 7F; Table I in the online-only Data Supplement).
Discussion
The development of an atherosclerotic plaque is characterized by the recruitment of blood-borne mononuclear cells, such as monocytes and lymphocytes, into the vessel wall and the production of proinflammatory mediators. Inflammation is thought to contribute to acute cardiovascular events by promoting the production of MMPs, which in turn weaken the mechanical strength of collagen, a main structural component of the fibrous cap. 31 Expression of these molecules is normally tightly regulated. However, during development of atherosclerosis, their expression is upregulated for extended periods of time, promoting inflammation and tissue destruction.
Although targeting of a myriad of inflammatory mediators and their receptors in mice prevents the development of atherosclerotic lesions, 31 translation in humans has not yet been achieved. This is potentially due to differences in lipid metabolism and inflammation between mice and humans 32 and a lack of experimental tools to test efficacy in human atherosclerotic lesions in the preclinical phase. We developed a short-term cell culture system whereby cells contained in human carotid endarterectomies can be isolated alive and used for functional analyses. We demonstrated that cells isolated from human atherosclerotic lesions are characterized in culture by a dysregulated production of cytokines, which is NF-B dependent. 23 In the present study, we dissected upstream signaling components with the potential to drive NF-B activation.
TLRs are key inducers of NF-B signaling 3 and share the signaling adaptor MyD88 with IL-1R. Previous studies in mice have shown that genetic deletion of MyD88 or TLR-2 prevents atherosclerosis development and macrophage infiltration. 6, 9, 10 Interestingly, the decrease in lesion size is associated with a reduction of serum cholesterol levels. 6, 9, 10 In our study, we observed that interruption of TLR-2 and MyD88 signaling in cells isolated from human atherosclerotic lesions had a direct effect on NF-B activation, as well as cytokine and chemokine production. Both MyD88 and TLR-2 blockade did not affect TNF-␣ levels. In our previous studies, TNF-␣ production by atheroma cell culture was dependent on the function of the NF-B pathway. 25 The different levels of TLR dependence observed with the various mediators analyzed could be explained by a redundancy of signaling mechanisms in the complex human atheroma microenvironment. The lack of effect on TNF-␣ could be explained alternatively by the kinetics displayed by TNF-␣ release in our cell culture system, whereby TNF-␣ peaks at 24 hours, and subsequently its production fades away rapidly, and its levels become undetectable. The kinetics of other cytokines and chemokines were characterized by a steady increase over the 96-hour period in culture. Indeed, the effectiveness of TLR-2 and MyD88 inhibition on the production of these proinflammatory mediators also increased over time.
The current consensus view of the mechanisms leading to plaque rupture has assigned a central role to MMP-dependent collagen degradation. Increased expression of MMP-1 (collagenase), -3 (stromelysin), and -9 (gelatinase) has been observed in the shoulder of human carotid plaques in association with macrophages and smooth muscle cells. 33 Levels of gelatinases, such as MMP-9, are predictors of adverse events in coronary artery disease and carotid artery disease. 33 Polymorphisms of haplotypes leading to an increase in MMP-1 and -3 activity increase the risk of myocardial infarction and stroke. 34 The potential involvement of TLR signaling in the regulation of MMP production has not yet been proven. Herein, we show that TLR-2 and MyD88 blockade not only blocked proinflammatory mediators, but it was also effective in reducing production of MMPs, suggesting that TLR signaling influences plaque vulnerability to rupture. Stimulation of macrophages and smooth muscle cells by proinflammatory cytokines, such as IL-1, leads to MMP expression. 35 Because of the nature of the model system utilized, we are unable to discriminate whether the reduction of MMP release in the atheroma cell culture is attributable to TLR signaling blockade or secondary to cytokine inhibition. However, our finding that IL-1Ra did not affect MMP release indicates that TLR signaling plays a dominant role in extracellular matrix catabolism in the human atherosclerotic plaque.
IL-1 is a prototypic inflammatory cytokine that exists in 2 forms, IL-1␣ and IL-1␤, both of which exert similar biological functions mediated through the IL-1R. IL-1Ra is a naturally occurring cytokine that binds to IL-1R but does not elicit a biological response. 36 A variety of studies have shown reduction of atherosclerotic lesion formation in hyperlipidemic mice via overexpression of IL-1Ra or IL-1 deletion. 7, 8 Surprisingly, in our study IL-1 blockade by IL-1Ra reduced IL-6 release in atheroma cell cultures but not chemokine or MMP release. Hence, MyD88-dependent signaling in human atherosclerosis appears to be predominantly dependent on TLR rather than IL-1R signaling.
TLR-4 is unique among TLRs in being able to activate both the MyD88-dependent and the MyD88-independent pathways, leading to NF-B and interferon regulatory factor-3 signaling. 1, 3, 5, 37 TLR-4 genetic deletion in mice was associated with a reduction of atherosclerotic lesions, macrophage recruitment, and cholesterol levels. 9 In our study, blockade of TLR-4 signaling in human plaques, either via neutralizing antibodies or via overexpression of a dominantnegative form of the downstream TLR-4 signaling adaptor TRAM, reduced endogenous NF-B activation in atheroma cells. This degree of inhibition of NF-B activation did not achieve a significant downregulation of the NF-B-dependent cytokines, such as TNF-␣, IL-6, IL-8/CXCL8, and MCP-1/CCL2. We attempted to measure interferon regulatory factor-3-dependent genes, such as interferon-␤, CXCL10, and CXCL11, but these mediators were below detection limits (data not shown). This could be either due to their low abundance or due to the fact that they are not part of the dysregulated cytokine production we sought to study. Therefore, we focused on NF-Bdependent responses, which we characterized previously. 25 The role of TRAM not only is limited to interferon regulatory factor-3 signaling but is required for late NF-B activation and NF-B-dependent gene production (eg, IL-6). 1, 3, 5, 37 Blockade of TRAM does not affect IL-6 production in the atheroma cell culture. This finding indicates a prevalent role of MyD88 in NF-B-dependent proinflammatory responses in human atherosclerosis. Nevertheless, we uncovered a role for TLR-4/TRAM-dependent signaling in MMP production, suggesting that the MyD88-independent pathway may play a role in mechanisms related to matrix degradation and plaque vulnerability. Because TLR-4 can also signal through MyD88, we are unable to draw definite conclusions about the role of TLR-4 signaling. However, given the significant impact of TLR-2 blockade, a possible interpretation of our data is that TLR-2 might account for most of the MyD88-dependent responses. This ex vivo model system of short-term culture of atheroma cells is not without potential limitations. The atheroma cell culture studies production of mediators by mixed cell populations. 25 Further separation of different cell types is avoided to minimize cell manipulation and activation and is also limited by low cell numbers. As a result, we were not able to pinpoint the specific cell type affected by TLR blockade. Mullick et al 10 have shown that, in contrast to whole-body deficiency of TLR-2, bone marrow transfer from TLR-2 Ϫ/Ϫ to low-density lipoprotein receptor Ϫ/Ϫ mice was effective in preventing exogenous TLR-2 ligand-induced disease amplification but not baseline atherosclerotic lesion formation. This finding points toward a key role for TLR-2 expression in vascular cells. 15 Of relevance, only endothelial cells, but not myeloid cells, express TLR-2 in murine lesions. 15 However, in human lesions, TLR-2 expression was detected in macrophages, endothelial cells, and smooth muscle cells. 16 Hence, TLR-2 blockade in human atherosclerosis may affect all cell types in the lesions. Differences in expression in TLR-2 could result either from differences between early versus late disease stage or a difference between murine and human atherosclerosis. Moreover, the technique used to isolate and culture cells from atherosclerotic lesions, based on the well-established culture of synovial cells from the joints of patients with rheumatoid arthritis, 38 has the potential for cell culture-and isolation-induced artifacts (eg, some degree of cell activation). However, no such cytokine production can be observed in cells cultured from atherosclerosis-free human vascular tissues, reflecting either a different cellular composition of these specimens or activation state of the cells during disease. 25 Finally, we acknowledge the possibility that the atheroma cell culture system does not fully represent TLR-4 signaling in vivo. For instance, lipopolysaccharide contamination could lead to TLR-4 hyporesponsiveness. We addressed this concern by excluding lipopolysaccharide contamination via the sensitive Limulus amebocyte assay (Methods in the online-only Data Supplement) in supernatants and in enzymatic mixtures. An alternative explanation is the subversion of the extracellular matrix components during cell isolation. TLR-4 signaling is inhibited by intact extracellular matrix components, 39 whereas extracellular matrix fragments might activate signaling. 2 In support of this concept, TLR responses are attenuated during atherosclerosis progression, and fibronectin extra domain A fragment might have a role in TLR signaling tolerance. 24 However, it is worth noting that, although matrix components may be present in the atheroma cell culture, they could also affect TLR-2 signaling. 24, 40 We conclude that TLR-2/MyD88-dependent signaling is a key pathway in maintaining the proinflammatory and procatabolic phenotype of cells isolated from human atherosclerotic lesions. Our study highlights differences between human and mouse atherosclerosis that might guide therapeutic applications of TLR blockade in cardiovascular disease. Given the diversity of bacterial signatures 41 and potential endogenous ligands [42] [43] [44] detected in human atherosclerotic lesions, TLR-2 blockade may be a "broad" therapeutic strategy for atherosclerosis and its complications.
